Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 23, 2007

Medarex and Compugen Partner on Mab-Based Therapeutics in Oncology and Autoimmune Diseases

  • Medarex and Compugen are partnering to develop Mab-based therapeutics for oncology and autoimmune diseases.
    Compugen expects to utilize its antibody-target discovery engine to identify drug targets. Medarex plans to develop fully human antibodies against these targets using its UltiMAb Human Antibody Development System®.

    The collaboration also provides that Compugen may independently pursue diagnostic applications involving certain antibodies and targets.

    Under the terms of the agreement, Medarex and Compugen plan to share discovery, development, and commercialization responsibilities as well as revenues generated from the sale of any therapeutic products resulting from this collaboration.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »